Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients

Journal of Clinical Oncology

Volumn 21, Issue 20, 2003, Pages 3826-3835

  Bedrosian, Isabelle ^a   Mick, Rosemarie ^a   Xu, Shuwen ^a   Nisenbaum, Harvey ^a   Faries, Mark ^a   Zhang, Paul ^a   Cohen, Peter A ^a   Koski, Gary ^a   Czerniecki, Brian J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; CANCER VACCINE;

ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; FEASIBILITY STUDY; FEVER; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; INTRANODAL DRUG ADMINISTRATION; LYMPHOCYTE FUNCTION; MAXIMUM TOLERATED DOSE; MELANOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSITIZATION; ADOPTIVE IMMUNOTHERAPY; ADULT; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; FEMALE; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE; MALE; METASTASIS; MIDDLE AGED; OUTCOME ASSESSMENT; VACCINATION;

ADMINISTRATION, CUTANEOUS; ADULT; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRAVENOUS; LYMPH NODES; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; OUTCOME ASSESSMENT (HEALTH CARE); VACCINATION;

EID: 0142055970     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.042     Document Type: Article

References (24)

1. Banchereau J, Palucka A, Dhodapkar M, et al: Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 61:6451-6458, 2001
2. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332, 1998
3. Thurner B, Haendle I, Roder C, et al: Vaccination with Mage-3A1 peptide-pulsed mature monocyte-derived dendritic cells expands specific cytoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-1678, 1999
4. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granuloctye/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109-1118, 1994
5. Sallusto F, Cella M, Danieli C, et al: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products. J Exp Med 182:389-400, 1995
6. Zhou L, Tedder T: CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 93:2588-2592, 1996
7. Reddy A, Sapp M, Feldman M, et al: A monocyte-conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 90:3640-3646, 1997
8. Palucka K, Taquet N, Sanchez-Chapuis F, et al: Dendritic cells as the terminal stage of monocyte differentiation. J Immunol 160:4587-4595, 1998
9. Czerniecki B, Carter C, Rivoltini L, et al: Calcium ionophore treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J Immunol 159:3823-3837, 1997
10. Koski GK, Schwartz GN, Weng DE, et al: Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways. J Immunol 163:82-92, 1999
11. Butterfield L, Ribas A, Dissette V, et al: Determinant spreading associated with clinical response in dendritic cell-based therapy for malignant melanoma. Clin Cancer Res 9:998-1008, 2003
12. Lau R, Wang F, Jeffrey G, et al: Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24:66-78, 2001
13. Morse M, Deng Y, Coleman D, et al: A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5:1331-1338, 1999
14. Murphy G, Tjoa B, Simmons S, et al: Infusion of dendritic cells pulsed with HLA-A2 specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38:73-78, 1999
15. Dhodapkar M, Steinman R, Krasovsky J, et al: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233-238, 2001
16. Jonuleit H, Giesecke-Tuettenberg A, Tutling T, et al: A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T cell responses in humans following intranodal injection. Int J Cancer 93:243-251, 2001
17. Lambert L, Gibson G, Maloney M, et al: Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 61:641-646, 2001
18. Therasse P, Arbuck S, Eisenhauer E, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-217, 2000
19. Faries M, Bedrosian I, Xu S, et al: Calcium signaling inhibits IL-12 production and activates CD83+ dendritic cells that induce Th2 development. Blood 98:2489-2497, 2001
20. Barth R, Mule J, Asher A, et al: Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 173:647-658, 1991
21. Mosca P, Hobeika A, Clay T, et al: A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood 96:3499-3504, 2000
22. Hilkens CM, Kalinski P, de Boer M, et al: Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 90:1920-1926, 1997
23. Snijders A, Kalinski P, Hilkens C, et al: High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 10:1593-1598, 1998
24. Xu S, Koski G, Faries M, et al: Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12 dependent mechanism. J Immunol 171:2251-2261, 2003